Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1995 May;86(5):490–500. doi: 10.1111/j.1349-7006.1995.tb03083.x

Phase I Study and Clinical Pharmacological Evaluation of Daily Oral Etoposide Combined with Carboplatin in Patients with Lung Cancer

Terumasa Ohune 1, Yasuhiro Fujiwara 1,2,✉, Hidetaka Sumiyoshi 1, Naoki Yamaoka 1, Michio Yamakido 1
PMCID: PMC5920854  PMID: 7790322

Abstract

Twenty‐eight patients with inoperable or relapsed lung cancer were given a combination of oral etoposide, administered once a day at doses ranging from 40 to 60 mg/m2/day (d) for 21 consecutive days, and carboplatin, administered intravenously over 1 h at doses ranging from 300 to 400 mg/m2 on day 1 to determine the appropriate doses of this combination. In addition, pharmacokinetic and pharmacodynamic analyses were performed. All the patients had a performance status of 0 to 1. Serum etoposide and free platinum (Pt) concentrations were measured using high‐performance liquid chromatography and atomic absorption, respectively. Myelosuppression, nausea and vomiting were the dose‐limiting toxicities of this schedule. The maximum tolerated dose (MTD) was 50 mg/m2/d oral etoposide for 21 days and 400 mg/m2 i.v. carboplatin on day 1. For heavily pretreated patients, the MTD was 40 mg/m2/d oral etoposide for 21 days and 350 mg/m2 i.v. carboplatin on day 1. No cumulative increase in the area under the concentration‐time curve (AUC) for oral etoposide over time was observed. There were significant correlations between the free Pt serum level (6, 8, 12, 24 h post‐dose) and etoposide AUC level (days 1, 10 and 21) for graded hematological toxicity, and the percentage decreases and nadir counts of hemoglobin, leukocytes, neutrophils and platelets. Several pharmacodynamic models were developed to predict the hematological toxicity. In order to facilitate pharmacodynamic evaluations in future studies, a limited sampling model for oral etoposide was also developed and validated.

Keywords: Oral etoposide, Carboplatin, Pharmacokinetics, Pharmacodynamics, Lung cancer

Full Text

The Full Text of this article is available as a PDF (646.4 KB).

REFERENCES

  • 1).Johnson , D. H. , Hainsworth , J. D. , Hande , K. R. and Greco , F. A.Current status of etoposide in the management of small cell lung cancer . Cancer , 67 , 231 – 244 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 2).Klastersky , J. , Sculier , J. P. , Lacroix , H. , Dabouis , G. , Bureau , G. , Libert , P. , Richez , M. , Ravez , P. , Vandermoten , G. , Thiriau , J. , Cordier , R. , Finet , C. , Berchier , M. C. , Sergysels , R. , Mommen , P. and Paesmans , M.for the European Organization for Research and Treatment of Cancer Lung Cancer Working Party. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non‐small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07681 . J. Clin. Oncol. , 8 , 1556 – 1562 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 3).Hainsworth , J. D. , Johnson , D. H. , Frazier , S. R. and Greco , F. A.Chronic daily administration of oral etoposide — a phase I trial . J. Clin. Oncol. , 7 , 396 – 401 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 4).Johnson , D. H. , Greco , F. A. , Strupp , J. , Hande , K. R. and Hainsworth , J. D.Prolonged administration of oral etoposide in patients with relapsed or refractory small‐cell lung cancer: a phase II trial . J. Clin. Oncol. , 8 , 1613 – 1617 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 5).Waits , T. M. , Johnson , D. H. , Hainsworth , J. D. , Hande , K. R. , Thomas , M. and Greco , F. A.Prolonged administration of oral etoposide in non‐small cell lung cancer: a phase II trial . J. Clin. Oncol. , 10 , 292 – 296 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 6).Hande , K. R.Drug monitoring in cancer therapy . J. Natl. Cancer Inst. , 83 , 1523 – 1524 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 7).Ratain , M. J. , Schilsky , R. L. , Conley , B. A. and Egorin , M. J.Pharmacodynamics in cancer therapy . J. Clin. Oncol. , 8 , 1739 – 1753 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 8).Ratain , M. J. and Vogelzang , N. J.Limited sampling model for vinblastine pharmacokinetics . Cancer Treat. Rep. , 71 , 935 – 939 ( 1987. ). [PubMed] [Google Scholar]
  • 9).Tsuya , T. , Yamaoka , N. , Hasegawa , K. and Yamakido , M.Prolonged administration of oral etoposide to patients with lung cancer . J. Hiroshima Med. Assoc. , 44 , 15 – 18 ( 1991. ) ( in Japanese ). [Google Scholar]
  • 10).Bunn , P. A.Review of therapeutic trial of carboplatin in lung cancer . Semin. Oncol. , 16 ( Suppl. 5 ), 27 – 33 ( 1989. ). [PubMed] [Google Scholar]
  • 11). “ WHO Handbook for Reporting Results of Cancer Treatment ” ( 1979. ). World Health Organization; , Geneva . [Google Scholar]
  • 12).Allen , L. M.Analysis of 4′‐demethylepipodophyllotoxin‐9‐(4,6‐O‐ethylidene‐β‐D‐glucopyranoside) by high‐pressure liquid chromatography . J. Pharm. Sci. , 69 , 1440 – 1441 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 13).LeRoy , A. F. , Wehling , M. L. , Sposeller , H. L. , Friauf , W. S. , Solomon , R. E. and Dedrick , R. L.Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry . Biochem. Med. , 18 , 184 – 191 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 14).Yamaoka , K. and Tanigawara , Y.Program for an automated pharmacokinetic analysis system . In “ Introduction to Pharmacokinetic Analysis ” ( 1983. ). Nankodo; , Tokyo ( in Japanese ). [Google Scholar]
  • 15).Sheiner , L. B. and Beal , S. L.Some suggestions for measuring predictive performance . J. Pharmacokinet. Biopharm. , 9 , 503 – 512 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 16).van der Vijgh , W. J. F.Clinical pharmacokinetics of carboplatin . Clin. Pharmacokinet. , 21 , 242 – 261 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 17).Newell , D. R. , Eeles , R. A. , Gumbrell , L. A. , Boxall , F. E. , Horwich , A. and Calvert , A. H.Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma . Cancer Chemother. Pharmacol. , 23 , 367 – 372 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 18).Jelliffe , R. W.Creatinine clearance: bedside estimate . Ann. Intern. Med. , 79 , 604 – 605 ( 1973. ). [DOI] [PubMed] [Google Scholar]
  • 19).Clark , P. I. and Slevin , M. L.The clinical pharmacology of etoposide and teniposide . Clin. Pharmacokinet. , 12 , 223 – 252 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 20).Balis , F. , Holcenberg , J. , Tubergen , D. , Ames , M. , Murphy , R. , Waskerwitz , M. , Gilchrist , G. , Sather , H. , Bleyer , A. and Poplack , D.CCG 105PH: population pharmacokinetics (PK) of oral methotrexate (MTX) and mercaptopurine (MP) in children with acute lymphoblastic leukemia (ALL) . Proc. Am. Soc. Clin. Oncol. , 12 , 318 ( 1993. ). [Google Scholar]
  • 21).Egorin , M. J. , Van Echo , D. A. , Tipping , S. J. , Olman , E. A. , Whitacre , M. Y. , Thompson , B. W. and Aisner , J.Pharmacokinetics and dosage reduction of cis‐diammine (1,1‐cyclobutane‐dicarboxylato)platinum in patients with impaired renal function . Cancer Res , 44 , 5432 – 5438 ( 1984. ). [PubMed] [Google Scholar]
  • 22).Calvert , A. H. , Newell , D. R. , Gumbrell , L. A. , O'Reilly , S. , Burnell , M. , Boxall , F. E. , Siddik , Z. H. , Judson , I. R. , Gore , M. E. and Wiltshaw , E.Carboplatin dosage: prospective evaluation of a simple formula based on renal function . J. Clin. Oncol. , 7 , 1748 – 1756 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 23).Jordell , D. I. , Egorin , M. J. , Canetta , R. M. , Langenberg , P. , Goldbloom , E. P. , Burroughs , J. N. , Goodlow , J. L. , Tan , S. and Wiltshaw , E.Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer . J. Clin. Oncol. , 10 , 520 – 528 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 24).Belani , C. P. , Egorin , M. J. , Abrams , J. S. , Hiponia , D. , Eisenberger , M. , Aisner , J. and Van Echo , D. A.A novel pharmacologically based approach to dose optimization of carboplatin when used in combination with etoposide . J. Clin. Oncol. , 7 , 1896 – 1902 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 25).Jones , R. B. , Matthes , S. , Shpall , E. J. , Fisher , J. H. , Stremmer , S. M. , Dufton , C. , Stephens , J. K. and Bearman , S. I.Acute lung injury following treatment with high‐dose cyclophosphamide, cisplatin and carmustine: pharmacodynamic evaluation of carmustine . J. Natl. Cancer Inst. , 85 , 640 – 647 ( 1993. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES